Viridian Therapeutics, Inc. (VRDN)
18.66
+0.32
(+1.74%)
USD |
NASDAQ |
Oct 09, 16:00
18.69
+0.03
(+0.16%)
Pre-Market: 20:00
Viridian Therapeutics Free Cash Flow : -335.52M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -335.52M |
| March 31, 2026 | -304.30M |
| December 31, 2025 | -277.36M |
| September 30, 2025 | -326.34M |
| June 30, 2025 | -309.60M |
| March 31, 2025 | -280.35M |
| December 31, 2024 | -232.83M |
| September 30, 2024 | -197.43M |
| June 30, 2024 | -168.82M |
| March 31, 2024 | -168.20M |
| December 31, 2023 | -185.07M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -68.28M |
| March 31, 2022 | -64.59M |
| December 31, 2021 | -54.92M |
| September 30, 2021 | -47.72M |
| June 30, 2021 | -40.81M |
| March 31, 2021 | -32.92M |
| December 31, 2020 | -29.82M |
| Date | Value |
|---|---|
| September 30, 2020 | -28.20M |
| June 30, 2020 | -32.34M |
| March 31, 2020 | -32.75M |
| December 31, 2019 | -36.14M |
| September 30, 2019 | -36.56M |
| June 30, 2019 | -34.28M |
| March 31, 2019 | -31.68M |
| December 31, 2018 | -27.29M |
| September 30, 2018 | -26.34M |
| June 30, 2018 | -25.06M |
| March 31, 2018 | -27.64M |
| December 31, 2017 | -28.41M |
| September 30, 2017 | -24.43M |
| June 30, 2017 | -26.18M |
| March 31, 2017 | -21.01M |
| December 31, 2016 | -15.00M |
| September 30, 2016 | -13.03M |
| June 30, 2016 | -7.891M |
| March 31, 2016 | -8.093M |
| December 31, 2015 | -7.021M |
| September 30, 2015 | -6.958M |
| June 30, 2015 | -5.452M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.796B |
| TG Therapeutics, Inc. | 17.38M |
| Travere Therapeutics, Inc. | 15.40M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -105.32M |
| Cash from Investing (Quarterly) | -231.16M |
| Cash from Financing (Quarterly) | 325.12M |
| Free Cash Flow Per Share (Quarterly) | -0.9884 |
| Free Cash Flow to Equity (Quarterly) | -298.34M |
| Free Cash Flow to Firm (Quarterly) | -98.32M |
| Free Cash Flow Yield | -18.62% |